We are excited about the data and plan to submit the data for publication and peer reviewed medical journal in the near term.

$AVXL Australia trial data meets the gold standard.

$AVXL - Alz Topline Data was solid ..

Efficacy is likey overwhelming after seeing 👀 data details!

$AVXL I am extremely bullish on the data .. the FDA can ask any sorts of questions

I'm looking forward to seeing the long term AD data on ANVS and have the feeling it's going to end up being the best in class AD treatment as well.

Now DATA met expectations.

Also clint said every time Blarcamesine data comes back it looks better and better. .

Anavex has significant 4 years of ph2/3 safety data with safety back to 2013 for Blarcamesine .. anavex has full 3 endpoint trial and a placebo .. it's obvious Anavex wins!!

So I think the data so far was encouraging,

Data tells me no safety issues, with a possible large therapeutic window.

Then they dropped the “good” totally “not disappointing” data that Remi was so “Thrilled” about.

This will go beyond parabolic on good data … literally no shares out there unless they offer new ones … $MDGL $VKTX $SLS $SAVA

SAVA data gets analyzed by multiple different labs and shows its cognition improvement in mild AD cases, safe and well-tolerated

$SAVA I love not being able to hold $28 off data that will keep it pinned here until 2024.

but the data to date would predict continued efficacy that will be nigh on impossible to ignore.

Data teasing is very positive. 🚀

$SAVA Institutional buying says data is good!! !

I’ll keep buying until data comes out…

Excited for the next data unveiling….bring it on!

ATNM just published very good data from their P3 trail which is great news for Acute myeloid leukemia patients.

but this time they look way more stronger and aggressive with the data.

Translate the data on this (today's sec release) Seems VERY positive and with a cash run into 2024 on worst case basis.

Watching $TGTX PDUFA data in the coming days and congrats to those who held on to $VRNA big win today.

up 290% After Positive Resmetirom Liver Treatment Phase3 Trial data.